D igoxin has been used for centuries to treat heart failure.
However, as a result of its narrow therapeutic window and its potential contribution to life-threatening ventricular tachyarrhythmias and severe bradyarrhythmias, its use in atrial fibrillation (AF) has remained controversial. 1 Several randomized clinical trials in heart failure patients without AF have shown clinical benefits. [2] [3] [4] The largest of these studies, the Digitalis Investigation Group (DIG) trial found that digoxin had a neutral effect on mortality and modestly reduced hospitalizations because of worsening heart failure. 4 Of note, however, this happened in the setting of strict monitoring of serum digoxin concentrations. 5 Subsequently, several large-scale observational studies reported that digoxin therapy was associated with increased cardiovascular mortality. [6] [7] [8] For instance, Freeman et al using data from a large administrative database recently reported that digoxin use in patients with incident systolic heart failure was independently associated with increased total mortality. 8 Concerning the use of digoxin for rate control in AF, there have also been reports on increased mortality. In the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) trial, digoxin was associated with higher all-cause mortality (hazard ratio [HR], 1.42; 95% confidence interval [CI], 1.09-1.86). 9 These findings were recently confirmed after correcting for clinical characteristics and comorbidities. 10 Similarly, digoxin use was also associated with increased all-cause and cardiovascular mortality in the setting of electric cardioversion of AF. 11 the study 12 and to a contraindication of this agent in permanent AF. Dronedarone increases digoxin plasma concentration by a pharmacokinetic interaction as it is potent inhibitor of the P-glycoprotein transport system. 13 Therefore, investigators were advised to use digoxin with caution and monitor serum levels closely. We did observe higher digoxin concentrations in patients randomized to dronedarone. We therefore hypothesized that the dronedarone-digoxin interaction might in part explain either the increased risk of cardiovascular death or the increased risk of heart failure associated with dronedarone in PALLAS. The present analysis was designed to examine these hypotheses.
Methods

The PALLAS Trial
The design and the results of the PALLAS trial have been reported in detail. 12 Briefly, PALLAS was designed to determine if dronedarone would reduce major vascular events in patients with permanent AF. Permanent AF was defined as ECG documentation of AF or flutter within 14 days of randomization and also ≥6 months before, with no evidence of sinus rhythm intervening and with no plans to restore sinus rhythm. Patients had to be ≥65 years with ≥1 risk factor for cardiovascular events. Eligible patients were randomized double-blind to receive dronedarone 400 mg twice daily or matching placebo. The first co-primary outcome was a composite of stroke, myocardial infarction, systemic embolism, or cardiovascular death. The second co-primary outcome was unplanned cardiovascular hospitalization or death. Other outcomes were death from cardiovascular causes, death from arrhythmia, hospitalization for heart failure or heart failure episode without hospitalization, and death from any cause. Heart failure events (without hospitalization) were defined as new or worsening signs or symptoms of heart failure requiring intensification of heart failure treatment. The trial was approved by the ethics committee at each participating center, and subjects gave informed consent. The Data Monitoring Committee recommended on July 5, 2011, that the study should be terminated for safety. At study closure, 3236 out of 10 800 planned patients had been randomized and followed for a mean of 4.2 months.
Measurement of Serum Digoxin
Patients were to be seen at 7 and 30 days after randomization and then at month 4 and every 4 months thereafter. As dronedarone can increase serum digoxin concentration, 13 investigators were advised to use digoxin with caution and monitor serum levels closely. A serum concentration of digoxin was measured at day 7 in patients receiving glycosides. There were no significant differences in patient characteristics for dronedarone vs placebo in the digoxin and in the no-digoxin subgroups. The rate of prior myocardial infarction is not significantly different in the dronedarone and placebo group within the digoxin subgroup (21.5% vs 26.2%; P=0.07).
ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; CAD, coronary artery disease; NYHA, New York Heart Association; and LVEF, left ventricular ejection fraction. 
Statistics
The analysis was focused on fatal outcomes, including cardiovascular and arrhythmic death and on heart failure events. All primary and secondary events in the trial, including deaths, were adjudicated in a blinded manner by a committee of experts. Cardiac deaths were classified as either arrhythmic or nonarrhythmic using the method of Hinkle and Thaler. 14 
Results
Patient Population
Of the 3236 enrolled patients, 1619 were assigned to receive dronedarone and 1617 to receive placebo. In the dronedarone group, 544 patients (33.6%) were on digoxin therapy at baseline compared with 526 (32.5%) in the placebo group. In both the placebo and dronedarone arms, patients receiving digoxin were more often females, were more likely to have advanced heart failure (New York Heart Association classes II and III), were more likely to have impaired left ventricular function, and were more often concomitantly treated with diuretics than patients not on digoxin (Table 1 ).
Serum Digoxin Concentrations
In Table 2 , the mean (median) serum digoxin concentrations are shown for both treatment groups. After randomization, digoxin serum concentrations were significantly higher in patients who had been assigned to dronedarone therapy.
Cardiovascular and Arrhythmic Mortality
Overall, among patients randomized to dronedarone, 21 patients had cardiovascular death (4.0%/year) compared with 10 (1.9%/year) randomized to placebo (HR, 2.11; 95% CI, 1.00-4.49; P=0.05; Table 3 ).
Overall, there were 13 arrhythmic deaths among patients randomized to dronedarone and 4 in patients randomized to placebo (HR, 3.26; 95% CI, 1.06-10.00; P=0.04). Among patients on digoxin, there were 11 arrhythmic deaths on dronedarone and 0 on placebo. Among patients not on digoxin, there were 2 arrhythmic deaths on dronedarone and 4 on placebo †Risk was estimated as an odds ratio from a logistic regression with 0.5 added to each group. December 2014 (P value for interaction 0.002; Table 3 ). As a sensitivity analysis, we also analyzed the data based on digoxin treatment on day 7 ( Table I in the Data Supplement). This analysis yielded similar inferences. Figure 1 shows the Kaplan-Meier plots for the 4 mortality outcomes in patients on dronedarone and placebo with or without concomitant digoxin therapy.
Heart Failure Outcomes
Overall, there was a significant increase in heart failure hospitalizations and in nonhospitalized heart failure events with dronedarone ( Table 4 ). For heart failure events (hospitalized or not), there were 55 events on placebo (10.7%/year) and 115 on dronedarone (23.2%/year); HR, 2.16; 95% CI, 1.57 to 2.98; P<0.001. There was, however, no evidence of an interaction between digoxin use and the hazard of developing heart failure from dronedarone. For patients on digoxin at baseline, the HR was 1.48; 95% CI, 0.86 to 2.54; P=0. 16 , and for patients not on digoxin at baseline, the HR was 2.62; 95% CI, 1.75 to 3.92; P<0.001 (interaction P value 0.10). Figure 2 shows the Kaplan-Meier plots for any heart failure events and for heart failure hospitalizations in patients on dronedarone and placebo with or without concomitant digoxin therapy.
Discussion
Main Findings
The main findings of this analysis are that there was a significant effect of digoxin use on the hazard of dronedarone for fatal outcomes, but there was no effect of digoxin use on the hazard of dronedarone for heart failure. In patients not on digoxin, dronedarone had no effect on mortality, whereas it markedly increased cardiovascular mortality and especially arrhythmic death in those receiving both medications. Although digoxin use was associated with worse heart failure, reduced ventricular function, diuretic use, and female sex, the significant dronedarone-digoxin interaction related to mortality persisted unchanged after adjustment for differences in baseline variables. This analysis is not conclusive and should be considered hypothesis generating; however, it does suggest that clinicians should be concerned about the combined use of dronedarone and digoxin. Furthermore, it supports the view that digoxin itself increases cardiovascular mortality, especially arrhythmic death, in patients with AF.
Prior Studies on the Safety of Digoxin Therapy
The use of digoxin for treatment of systolic heart failure is based on the results of 2 major withdrawal studies 2,3 and one large randomized initiation trial. 4 The DIG trial reported that there was no net effect of digoxin on mortality in patients with heart failure, but DIG was conducted before several advances in heart failure therapy, such as ACE inhibition or β-blockade, became the standard of therapy. Specifically, there was a 1.6% absolute reduction in heart failure death; however, other cardiac death (including death from arrhythmia) showed an absolute increase of 1.9% in the digoxin group. 4 More recently, several contemporary studies suggested a higher risk of death associated with digoxin therapy. [6] [7] [8] [15] [16] [17] [18] For instance, in studies with the oral anticoagulant, ximelagatran (SPORTIF III and V), digoxin use was associated with a hazard ratio of 1.58 (95% CI, 1.29-1.94) for all-cause mortality. 16 Freeman et al recently found in a series of 2891 newly diagnosed heart failure patients that digoxin use was associated with a hazard ratio of 1.72 (95% CIm 1.25-2.36) for mortality, 8 but they reported no significant difference in the risk of heart failure hospitalization. A secondary analysis of the AFFIRM trial reported that digoxin was associated with an increased adjusted risk of death, even after adjustment for baseline differences. 10
Potential Limitations of the Study
Because digoxin therapy was not randomized, it is possible that the present analysis is confounded by other variables, measured or unmeasured. In particular, it is possible that digoxin use is merely a marker for higher risk patients who would be more likely to display the adverse effects of dronedarone. In support of this argument is the fact that patients on digoxin were older and, in general, sicker than other patients. In favor of the observed interaction being a direct effect of digoxin is the fact that we observed no interaction related to combined use of digoxin and dronedarone related to heart failure. The specificity of the observed interaction for mortality, specifically arrhythmic death, together with the known potential for digoxin toxicity to cause serious brady-and tachyarrhythmias, suggests that the observed interaction is indeed directly related to digoxin.
Possible Reasons for Increased Mortality With Dronedarone and Digoxin
If the effect is real, then 2 possible mechanisms can be considered; the first is that increased digoxin itself is the driver of increased mortality in patients receiving dronedarone, and the second is that dronedarone increases arrhythmic death but only in patients on digoxin. A post hoc analysis of the DIG trial demonstrated an important association between serum digoxin concentrations and outcomes in patients with heart failure. 5 Higher serum digoxin concentrations were significantly associated with all-cause mortality rates with particularly high mortality among subjects with serum digoxin concentrations ≥1.2 ng/mL. The DIG authors therefore recommended that serum digoxin concentrations should be ideally in the range of 0.5 to 0.8 ng/mL 5 . Dronedarone increased serum digoxin concentration in PALLAS patients to a mean concentration of 1.2 ng/mL, a level well above the range recommended by the DIG study post hoc analysis. In PALLAS, investigators were well aware of such an interaction, and therefore, the study protocol called for regular determination of serum digoxin concentrations at day 7. Despite these precautions, 6 of 8 serum digoxin concentrations available at day 7 in patients who suffered from arrhythmic death in PALLAS were ≥1.2 ng/mL. It is possible that the increased mortality seen in PALLAS with combined dronedarone and digoxin is caused by the pharmacokinetic interaction between dronedarone and digoxin that resulted in higher digoxin concentrations, which in turn increased mortality but not heart failure. On the other hand, we cannot exclude the possibility that the increased arrhythmic deaths on the combination of digoxin and dronedarone is a unique toxicity related to the combined use of the 2 agents, although this is a less compelling argument.
Clinical Implications
In the PALLAS trial, we have observed a harmful pharmacokinetic interaction between dronedarone and digoxin in patients with permanent AF. Our data suggest that this interaction was responsible at least in part for the higher death rate observed in the trial, particularly with respect to arrhythmic mortality. It does not, however, explain the increased risk of heart failure seen with dronedarone in PALLAS. These data are consistent with several other studies that indicate a potential hazard of digoxin use in AF and call into question the use of digoxin for rate control in atrial fibrillation, particularly because other suitable rate controlling drugs, such as β-blockers, are available and have excellent safety profiles.
